Psoriasis is a systemic, immune‐mediated disorder, characterized by inflammatory skin and
joint manifestations. A range of co‐morbidities is associated with psoriasis, including …

Pustular psoriasis ( PP ) is a group of inflammatory skin conditions characterized by infiltration
of neutrophil granulocytes in the epidermis to such an extent that clinically visible sterile …

… Dr Reich has received honoraria as consultant and/or advisory board member and/or acted
as paid speaker and/or participated in clinical trials sponsored by manufacturers of therapies …

Background Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We
evaluated secukinumab, a fully human anti–interleukin-17A monoclonal antibody, in …

Background Ustekinumab, a human monoclonal antibody against interleukins 12 and 23,
has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of …

This chapter assesses the scientific literature on projected changes in major climate phenomena
and more specifically their relevance for future change in regional climates, contingent …

… K Reich and FO Nestle contributed equally to this study. K Reich, FO Nestle, CEM Griffiths,
C … K Reich has served as a consultant and paid speaker for Centocor and Schering-Plough. …

Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem,
the consensus programme was performed to define goals for treatment of plaque psoriasis …

Background Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks
of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to …

… D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, JD Bos, GR
Burmester, S Chimenti, L Dubertret, B Eberlein, R Erdmann, J Ferguson, G Girolomoni, P …